A Randomized Phase II Study to Assess the Effect of Adjuvant Immunotherapy Using α-GalCer-pulsed Dendritic Cells in the Patients with Completely Resected Stage II-IIIA Non-small Cell Lung Cancer: Study Protocol for a Randomized Controlled Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2017 Sep 17

PMID 28915900

Citations 12

Authors

Hideo Saka

Chiyoe Kitagawa

Yukito Ichinose

Mitsuhiro Takenoyama

Hidenori Ibata

Tatsuo Kato

Koji Takami

Motohiro Yamashita

Tadashi Maeda

Sadanori Takeo

Hitoshi Ueda

Kan Okabayashi

Seiji Nagashima

Tadayuki Oka

Hidenori Kouso

Seiichi Fukuyama

Kentaro Yoshimoto

Mototsugu Shimokawa

Akiko M Saito

Suminobu Ito

Affiliations

Soon will be listed here.

Abstract

Background: As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II-IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only).

Methods: Subsequent to the complete resection of NSCLC, followed by the administration of cisplatin plus vinorelbine dual-agent combination adjuvant chemotherapy, patients who satisfy the inclusion criteria will be randomly allocated to either the α-GalCer-pulsed DC immune therapy group, or the standard treatment group. In total, 56 patients will be included in the study. The primary endpoint is recurrence-free survival, and the secondary endpoints are natural killer T-cell-specific immune response, the frequency of toxic effects and safety, and overall survival.

Discussion: In order to determine the efficacy of α-GalCer-pulsed DC therapy, the present study compares patients with stage II-III NSCLC who underwent complete surgical resection followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to those who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only).

Trial Registration: UMIN000010386 ( R000012145 ). Registered on 1 April 2013. UMIN-CTR is officially recognized as a registration site which satisfies ICMJE criteria.

Citing Articles

Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities.

Ganina A, Askarov M, Kozina L, Karimova M, Shayakhmetov Y, Mukhamedzhanova P Adv Respir Med. 2024; 92(6):504-525.

PMID: 39727496 PMC: 11673795. DOI: 10.3390/arm92060045.

Augmenting Granzyme B-Expressing NK Cells by Invariant NKT Ligand-Loaded APCs in Patients with Postoperative Early Stage Non-Small Cell Lung Cancer: Results of a Randomized Phase II Study.

Iyoda T, Shimizu K, Kawamura M, Shinga J, Watanabe T, Fukunaga K Immunohorizons. 2023; 7(1):1-16.

PMID: 36637516 PMC: 10563390. DOI: 10.4049/immunohorizons.2200091.

Manipulation of the immune system by non-small cell lung cancer and possible therapeutic interference.

Popper H Cancer Drug Resist. 2022; 3(4):710-725.

PMID: 35582213 PMC: 8992558. DOI: 10.20517/cdr.2020.40.

Adoptive cell therapies in thoracic malignancies.

Lasvergnas J, Naigeon M, Chouahnia K, Zelek L, Chaput N, Duchemann B Cancer Immunol Immunother. 2022; 71(9):2077-2098.

PMID: 35129636 PMC: 10992418. DOI: 10.1007/s00262-022-03142-3.

Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.

Zhu J, Yuan Y, Wan X, Yin D, Li R, Chen W Cochrane Database Syst Rev. 2021; 12:CD011300.

PMID: 34870327 PMC: 8647093. DOI: 10.1002/14651858.CD011300.pub3.

References

Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H . Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A. 1998; 95(10):5690-3. PMC: 20440. DOI: 10.1073/pnas.95.10.5690. View

Motohashi S, Kobayashi S, Ito T, Magara K, Mikuni O, Kamada N . Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer. 2002; 102(2):159-65. DOI: 10.1002/ijc.10678. View

Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M . A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005; 11(5):1910-7. DOI: 10.1158/1078-0432.CCR-04-1453. View

Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R . Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21):3552-9. DOI: 10.1200/JCO.2007.13.9030. View

Waller D, Peake M, Stephens R, Gower N, Milroy R, Parmar M . Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004; 26(1):173-82. DOI: 10.1016/j.ejcts.2004.03.041. View

Fujii S, Motohashi S, Shimizu K, Nakayama T, Yoshiga Y, Taniguchi M . Adjuvant activity mediated by iNKT cells. Semin Immunol. 2009; 22(2):97-102. DOI: 10.1016/j.smim.2009.10.002. View

Taniguchi M, Seino K, Nakayama T . The NKT cell system: bridging innate and acquired immunity. Nat Immunol. 2003; 4(12):1164-5. DOI: 10.1038/ni1203-1164. View

Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M . Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol. 1999; 163(5):2387-91. View

Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K . CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997; 278(5343):1626-9. DOI: 10.1126/science.278.5343.1626. View

10.

Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K . A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009; 182(4):2492-501. DOI: 10.4049/jimmunol.0800126. View

11.

Scagliotti G, Fossati R, Torri V, Crino L, Giaccone G, Silvano G . Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003; 95(19):1453-61. DOI: 10.1093/jnci/djg059. View

12.

Douillard J, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba J . Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7(9):719-27. DOI: 10.1016/S1470-2045(06)70804-X. View

13.

Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H . The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol. 2003; 21:483-513. DOI: 10.1146/annurev.immunol.21.120601.141057. View

14.

Fujii S, Shimizu K, Kronenberg M, Steinman R . Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol. 2002; 3(9):867-74. DOI: 10.1038/ni827. View

15.

Douillard J, Tribodet H, Aubert D, Shepherd F, Rosell R, Ding K . Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol. 2009; 5(2):220-8. DOI: 10.1097/JTO.0b013e3181c814e7. View

16.

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C . Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 352(25):2589-97. DOI: 10.1056/NEJMoa043623. View

17.

Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J, Vansteenkiste J . Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350(4):351-60. DOI: 10.1056/NEJMoa031644. View

18.

Akutsu Y, Nakayama T, Harada M, Kawano T, Motohashi S, Shimizu E . Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res. 2002; 93(4):397-403. PMC: 5927009. DOI: 10.1111/j.1349-7006.2002.tb01270.x. View

19.

Arriagada R, Dunant A, Pignon J, Bergman B, Chabowski M, Grunenwald D . Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2009; 28(1):35-42. DOI: 10.1200/JCO.2009.23.2272. View